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Abstract
Prebiotics are selectively fermented ingredients that result in specific changes in the composition 
and/or activity of the gastrointestinal microbiota, thus conferring benefit(s) upon the host health. 
The aim of this study was to evaluate the influence of a β (1–4) galacto-oligosaccharides 
formulation consisting of 90% pure GOS (GOS90), on the composition and activity of the mouse 
gut microbiota. Germ-free mice were colonized with microbiota from four pathogen-free wt 129 
mice donors (SPF), and stools were collected during a feeding trial in which GOS90 was delivered 
orally for 14 days. Pyrosequencing of 16S rDNA amplicons showed that Bifidobacterium and 
specific Lactobacillus, Bacteroides and Clostridiales were more prevalent in GOS90-fed mice after 
14 days, although the prebiotic impact on Bifidobacterium varied among individual mice. 
Prebiotic feeding also resulted in decreased abundance of Bacteroidales, Helicobacter and 
Clostridium. High-throughput quantitative PCR showed an increased abundance of 
Bifidobacterium adolescentis, B. pseudocatenulatum, B. lactis and B. gallicum in the prebiotic-fed 
mice. Control female mice showed a higher diversity (Phylogenetic Diversity PD = 15.1 ± 3.4 in 
stools and PD = 13.0 ± 0.6 in intestinal contents) than control males (PD = 7.8 ± 1.6 in stool 
samples and PD = 9.5 ± 1.0 in intestinal contents). GOS90 did not modify inflammatory 
biomarkers (IL-6, IL-12, IL-1β, IFN-γ and TNF-α). Decreased butyrate, acetate and lactate 
concentrations in stools of prebiotic fed mice suggested an increase in colonic absorption and 
reduced excretion. Overall, our results demonstrate that GOS90 is capable of modulating the 
intestinal microbiome resulting in expansion of the probiome (autochtonous commensal intestinal 
bacteria considered to have a beneficial influence on health).
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Introduction
Gut microorganisms live in a symbiotic interaction with the host and co-exist in a dynamic 
equilibrium while contributing to host physiology. The colon microbiota comprises 
populations of about 1011 cells/g that represent between 500 and 1,000 different species 
which are involved in the host’s metabolic, physiological and immune processes (1). Recent 
studies have correlated diseases like inflammatory bowel diseases (IBD), obesity, colorectal 
cancer, diabetes and allergies with imbalances in the composition of the gut microbial 
community (dysbiosis) (2–5). These findings have increased the interest in modulation of the 
gut microbial communities through dietary strategies to maintain health. One of these 
strategies is the consumption of prebiotics, which are currently defined as “selectively 
fermented ingredients that result in specific changes in the composition and/or activity of the 
gastrointestinal microbiota, thus conferring benefit(s) upon the host health” (6). Dietary 
interventions with prebiotics have been shown to selectively stimulate the growth and/or 
activity of health-promoting intestinal bacteria such as species of Bifidobacterium and 
Lactobacillus (7–10).
Galacto-oligosaccharides (GOS) are prebiotics recognized for their health benefits like 
modulation of the intestinal microbiota, alleviation of constipation, enhancing mineral 
absorption, prevention of carcinogenesis and mitigation of allergy (11, 12). GOS can also 
reduce the adherence of enteropathogens to the epithelial intestinal cells by functioning as 
receptor decoys that mimic mucosal cell surface glycans (13–16). Moreover, GOS are 
currently added to infant formula to stimulate growth of intestinal bifidobacteria and 
lactobacilli in order to obtain the health benefits of a “breastfed-like” microbiota (9).
Studies on GOS modulation of the gut microbiome showed that the prebiotic increased 
bifidobacteria populations in the human gastrointestinal tract of healthy individuals at the 
expense of less beneficial groups of Gram-negative bacteria such as Bacteroides and 
Desulfovibrio spp (10, 17–19). Additionally, a study conducted by Silk et al. (20) showed 
that GOS specifically stimulated gut bifidobacteria and alleviated symptoms like flatulence 
and abdominal pain in irritable bowel syndrome (IBS) patients. Moreover, a study conducted 
in overweight adults fed GOS showed increased secretory IgA and decreased fecal 
inflammatory markers such as calprotectin and plasma C reactive protein, as well as reduced 
metabolic syndrome markers such as insulin, total cholesterol (TC), triglycerides and 
TC:HDL cholesterol ratio (19), suggesting that GOS feeding stimulates the immune 
response and decreases the risk of developing cardiovascular diseases.
GOS molecules are synthesized enzymatically by β-galactosidases in a reaction known as 
transgalactosylation (12). However, the concentration and composition of GOS can vary 
with the method and enzyme used for their generation, which can influence their effect on 
the intestinal microbiota (21). For instance, it has been reported that mono- and di-
saccharides are the preferred substrate for Lactobacillus rhamnosus, while Bifidobacterium 
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lactis grows better in tri- and tetra-saccharides since it possesses specific transport systems 
that will import these more efficiently (22). In a previous study, we heterologously expressed 
a synthetically generated version of the hexosyltransferase gene (Bht) from Sporobolomyces 
singularis(23). The Bht gene encodes a glycosyl-hydrolase (EC 3.2.1.21) that acts as 
galactosyltransferase, able to catalyze a one-step conversion of lactose to GOS. Commercial 
GOS formulations such as Vivinal GOS (Friesland Domo), Oligomate (Yakult) and others 
contain only approximately 50% GOS (w/w), and also contain residual glucose, lactose and 
galactose. The high purity GOS (GOS90) preparation contains 90% GOS and 10% lactose 
(w/w), with no residual glucose or galactose.
The aim of the present study was to evaluate the influence of GOS90 on the composition of 
the transient and adherent components of the microbiota and their metabolic activity in wt 
129 mice.
Materials and methods
We hypothesized that the prebiotic would shift the composition and metabolic activity of the 
colon microbiota toward a more health-promoting community enriched with lactobacilli and 
bifidobacteria. To prove our hypothesis, mice of the 129 background were fed GOS90 over 
14 days. Stool samples were collected at three time points and intestinal contents were 
collected at the end of the trial in order to characterize and compare their bacterial 
communities by 16S amplicon pyrosequencing. In addition, we developed and optimized a 
high-throughput qPCR method using the BioMark platform by Fluidigm to identify and 
quantify Bifidobacterium species. Targeted metabolomic and cytokine analysis were carried 
out to determine the impact of prebiotic feeding in the production of short-chain fatty acids 
(SCFAs) and inflammatory markers.
Animal housing, treatment, and sample collection
Thirteen germ-free (GF) wt 129 mice (4 males and 9 females, 8–12 weeks old) were 
transferred to specific pathogen-free (SPF) conditions by colonization using gavage and 
rectal swabs prior to the experiment without any antibiotic treatment. Numbers of animals 
were based on minimum that would provide statistical power to validate differences between 
control and treatment. This was based on experience and published literature(24). The 
colonization inoculum consisted of stool samples from four SPF wt 129 mice born/raised not 
humanized. Nine stool pellets were suspended in 5 ml of phosphate buffered saline (PBS). 
The particulate matter was allowed to settle for approximately 5 minutes before inoculation. 
Nine days after colonization, mice were randomly divided into two groups: the control 
standard (Purina Prolab RMH3000) diet group consisting of 4 male and 3 female mice 
(cages 1 and 3) and 6 GOS90-fed female mice (cages 2 and 4). We allowed 9 days for the 
microbiota to stabilize based on a previous study that showed that after 1 week, the gut 
microbiota of gavage-colonized animals were more similar to the donor community than 
animals that had acquired their microbiota without intervention (24). Originally, the groups 
were planned to be 4 males and 3 females receiving GOS90, and 6 control females, but 3 of 
4 male mice would not provide stool samples on the day of the prebiotic treatment and 
consequently they were placed in the control group. Stool samples for those 3 mice were 
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collected at day 2. Fifty microliters of GOS90 syrup, the equivalent of 0.26 g/kg bodyweight 
of GOS (not including lactose), was delivered daily orally by pipette to the prebiotic-fed 
group for 14 days. The prebiotic dose was selected based on a previous study(25). No carrier 
solution (placebo) was provided to the control mice.
All fecal samples from prebiotic-fed mice were collected at three time points during the 
experiment: day 1 (no dietary modulation), day 7 and day 14. Day 1 was the first day of 
GOS feeding and stools were collected before delivering the prebiotic. All samples were 
stored at −80 °C immediately after collection. Animals were euthanized by CO2 inhalation 
followed by cervical dislocation. Colons were removed, flushed with PBS, and cut into 3 
sections – proximal, mid, and distal colon. These were each frozen in their own tube and 
kept at −80°C until analysis. All mouse protocols were approved by the Institutional Animal 
Care and Use Committee of the University of North Carolina at Chapel Hill.
Generation of GOS90
Production of highly pure GOS (90% GOS, 10% lactose, w/w) was carried out by standard 
transgalactosylation reactions utilizing a recombinant β-hexosyltransferase (BHT) from 
Sporobolomyces singularis expressed in Pichia pastoris as previously described(23). Since 
this preparation was generated using a BHT and not a β-galactosidase, the generated product 
was a highly-pure β (1–4) GOS free of residual glucose and galactose. Reactions were 
carried out using standardized amounts of enzyme (0.5 U g/1lactose) in 5 mM sodium 
phosphate buffer (pH 5.0) and a similarly buffered solution containing lactose (200 g/L) at 
30°C. Purity of the GOS90 product used in this study was determined as previously 
described (23, 27).
DNA isolation from fecal and intestinal content samples
All samples were kept frozen at −80°C until use. Prior to DNA extraction of the distal colon 
samples, the mucosal layer was gently scraped with a razor blade. The scraped material was 
placed in a microtube. At that time, DNA from fecal samples and intestinal samples (scraped 
material) was extracted using the QIAmp DNA Stool kit (Qiagen, Hilden, Germany). 
Modifications in the disruption step were made to the supplied protocol to ensure lysis of 
Gram-positive bacteria. In short, 200 mg of sample were transferred to a microtube 
containing 0.2 g of autoclaved glass beads (11 micron in diameter, Sigma) and 1.4 mL of 
ASL solution (Qiagen). Next, samples were homogenized in a TissueLyser II instrument 
(Qiagen, Valencia, Ca) at 25 Hz for 2 min. Following steps were performed according to the 
manufacturer’s protocol.
Barcoded 16S rRNA PCR and pyrosequencing
Amplicon pyrosequencing of the 16S ribosomal gene was performed as previously described 
(28, 29). Amplification of the V1–V2 region of the bacterial 16S rDNA gene was performed 
on total DNA from fecal and intestinal samples. Master mixes for these reactions included 
the Qiagen HotStar HiFidelity Polymerase Kit (Qiagen, Valencia CA) with a forward primer 
composed of the Roche Titanium Fusion Primer A (5’-
CCATCTCATCCCTGCGTGTCTCCGACTCAG -3’), a 10 bp Multiplex Identifier (MID) 
sequence (Roche, Indianapolis, IN) unique to each sample and the universal bacteria primer 
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8F (5'-AGAGTTTGATCCTGGCTCAG-3') (30). The reverse primer was composed of the 
Roche Titanium Primer B (5’-CCTATCCCCTGTGTGCCTTGGCAGTCTCAG -3’), the 
identical 10 bp MID sequence as the forward primer and the reverse primer 338R (5’-
GCTGCCTCCCGTAGGAGT-3’) (31). We also performed amplicon sequencing of 
fragments generated by PCR amplification using the Bifidobacterium-specific primer B-8F 
(5’-AGGGTTCGATTCTGGCTCAG-3’) (32) paired with the 338R as the reverse primer for 
specific detection of this genus. For intestinal content samples we used a combination (4:1) 
of the primers 8F and Bifido-8F with 338R as the reverse primer as described (32). PCR 
products were gel-purified individually using the E-Gel Electrophoresis System (Life 
Technologies, Invitrogen), and standardized prior to pooling. The 16S rDNA amplicons from 
the pooled sample were sequenced on a Roche 454 Genome Sequencer FLX Titanium 
instrument in the Microbiome Core Facility, Chapel Hill, NC using the GS FLX Titanium 
XLR70 sequencing reagents and protocols.
Amplicon sequencing data analysis
16S rRNA amplicon sequencing data was analyzed using the Quantitative Insights Into 
Microbial Ecology (QIIME) pipeline (33). Sequences were de-multiplexed, filtered for 
quality control and grouped into OTUs (Operational Taxonomic Units) at a 97% level to 
approximate species-level phylotypes using UCLUST with standard parameters (34). Next, 
chimeras and singletons were removed using ChimeraSlayer within QIIME (35). To ensure 
an even sampling depth, a random selection of 2,700 sequences (matching the sample with 
lowest number of reads) from each sample was used for rarefaction analysis to determine 
alpha diversity metrics (observed species and Phylogenetic Diversity indexes) on rarefied 
OTU tables. Beta diversity and principal coordinates analysis (PCoA) were also calculated 
within QIIME using Weighted and Unweighted Unifrac distances (36) between samples at a 
depth of 2,700 sequences per sample to evaluate dissimilarities between samples. 
Sequencing data obtained in this work has been registered as a bio project in NCBI 
(BioProject ID PRJNA291486)
PICRUSt analysis of 16S amplicon sequencing data
Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 
(PICRUSt) (http://picrust.github.com/picrust/) is a tool that predicts metagenome functional 
content from 16S rRNA amplicon sequencing input data. OTUs were picked to be used in 
PICRUSt using a Closed Reference OTU picking against the reference genome Greengenes 
database Version 13_8 (http://greengenes.secondgenome.com/). OTUs were assigned at 97% 
identity within QIIME using the UCLUST method (34).
Bifidobacterium species detection by 24.192 Dynamic array
The Access Array AA 24.192 (Fluidigm Corporation, San Francisco, CA, USA) in the 
Advanced Analytics Core at UNC (NC, USA) was used to detect specific Bifidobacterium 
species. The bacterial strains listed in Table 1 were used as controls in the study. All strains 
were grown in MRS + 0.5% cysteine at 37°C under anaerobic conditions (80% N2,10% 
CO2, and 10%, H2) in an anaerobic chamber (Coy Laboratory Products, MI, USA). Primers 
defined in previous studies (37–40) were used to amplify the 16S ribosomal RNA and the 
chaperonin GroEL genes (Table 2).
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Primers targeted the following: domain Bacteria, phylum Actinobacteria, genus 
Bifidobacterium and the Bifidobacterium species listed in Table 2. All primers were tested 
by standard PCR and conventional quantitative PCR using pure cultures of the strains listed 
in Table 1 and a pool of the strains at the same concentration. Standard PCR was performed 
using Qiagen HotStar HiFidelity PCR reagents and 50 ng of genomic DNA per reaction. 
PCR reactions were performed in duplicate under the following conditions: initial 
denaturation at 95°C for 1 minute, followed by 35 cycles of 95°C for 15 s, annealing at 60°C 
for 30 s, and extension at 72°C for 30 s, followed by a final 5 minute extension at 72°C. 
Conventional qPCR was performed using an ABI Prism 7000 (Applied Biosystems). The 
reaction mixture (20 µl) contained 2X power SYBRGreen PCR Master Mix, 200 nM of each 
primer and 2 µl of the DNA template. qPCR reactions were performed in triplicate under the 
following conditions: initial holding stage at 50°C for 2 minutes and 95°C for 10 minutes, 
followed by 35 cycles of 95°C for 15 s and 60°C for 1 min.
DNA from stool samples at a concentration of 25 ng/µl was used for high-throughput qPCR. 
To increase the template target yield, a pre-amplification (specific target amplification, STA) 
was performed before the Fluidigm Real-Time PCR according to recommendations from the 
manufacturer. This step consisted of a multiplex PCR reaction with a pool of the 13 primer 
sets. The reaction was performed using the following conditions: initial annealing at 95°C 
for 2 min, followed by 12 cycles of 95°C for 15 s and 60°C 4 min. After the STA reaction, 
products were diluted 5 times with TE buffer. Microfluidic qPCR was performed using a 
BioMark HD reader with a Dynamic Array 24.192 chip (Fluidigm). The 24.192 chip was 
processed following the manufacturer instructions. Briefly, 3 µl of the sample premix (2X 
SsoFast Evagreen supermix, 20X DNA binding Dye and 1.35 µl 5-fold diluted STA 
products) and 3 µl of the assay premix (2X assay loading buffer, 1X DNA suspension buffer, 
and 10µM each primer) were loaded into the chip. Finally, Real-Time PCR was performed 
following the next conditions: 95°C 60 s, followed by 35 cycles of 96°C for 5 s and 60°C for 
45 s.
In order to validate the method and obtain the Pearson’s correlation between the two diferent 
primer sets (16S and GroEL) used in this study, pure bacterial cultures of Bifidobacterium 
species (Table 1) at three different concentrations (25ng/µl, 2.5 ng/µl and 0.25ng/µ) were 
analyzed with their respective primers sets.
High-throughput qPCR data analysis
Raw data were normalized using the Livak method (47). Cq values for each sample were 
normalized against their respective Cq value obtained from Universal primers using the 
equation: Ratio (reference/target) = 2−Ct (ref)-Ct (target).
Targeted metabolome analysis
Target metabolites included 5 short-chain fatty acids (SCFAs: acetate, propanoate, 
isobutyrate, butyrate, valerate), and other relevant metabolites: succinate, glycerol, lactate, 
glucose, aminobutyrate and galactose. Briefly, approximately 40 mg of fecal samples were 
weighed and extracted with 1ml of water. 4-chlorophenylalanine and 13C-labeled hexanoic 
acid were used as internal standards. After centrifugation, a volume of 500 µl was used for 
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SCFA analysis with propyl chloroformate (PCF) derivatization, and a volume of 150 µl was 
used for analysis of other metabolites with methoxyamine and BSTFA derivatization. The 
derivates were analyzed with gas chromatograph-mass spectrometer (GC-MS) analysis at 
UNCG Metabolomics Facility (Kannapolis, NC).
Cytokine Analysis
Colon tissues (proximal and medium regions) were collected in 700 µl of sterile phosphate-
buffered saline (PBS) supplemented with complete EDTA-free protease inhibitor cocktail 
(Roche Applied Science, Indianapolis, IN, USA) and 0.1% IGEPAL. Colon tissues weighing 
between 300mg and 600mg were homogenized in a TissueLyser (Qiagen, Valencia CA) for 
5 min at 30 Hz at room temperature. Colon homogenates were centrifuged twice at 15,000 × 
g for 20 min at 4°C to remove cell debris, and the supernatants were aliquoted and stored at 
−80°C. Supernatants were used for cytokine analysis using an ELISA kit (Qiagen, Valencia 
CA) following the procedures recommended by the manufacturer. The cytokines analyzed 
were IFN-γ, IL-1β, IL-12, IL-6, IL-10 and TNF-α. Values were expressed as pg/mg protein. 
The mucosal protein content was determined using the Bradford assay (BioRad; Richmond, 
CA).
Statistical analyses
To identify bacterial taxa and biological pathways significantly impacted by prebiotic 
feeding, we used the non-parametric Mann-Whitney and Steel Dwass All Pairs test, which 
accounts for multiple comparisons, in JMP Genomics (SAS JMP Genomics 5.0). 
Differences in the abundance of bacterial taxa and pathways were analyzed between control 
and GOS90 at day 7 and at day 14. To test differences in microbial communities we 
performed Analyses of Similarity (ANOSIM) to calculate R and P values using the 
phylogeny-based unweighted UniFrac distance metric. For metabolomics and cytokine 
analysis, unpaired t tests were used to compare metabolites concentration between feeding 
groups (SAS JMP Genomics 5.0). P-values of less than 0.05 were considered significant.
Results
Microbiome composition of stools and intestinal contents of wt 129 mice
To assess the influence of GOS90 on the gut microbiome, we performed a community 
structure analysis of fecal samples of wt 129 SPF mice whose diet was supplemented or not 
(control) with 1% (0.26 g/kg/day) of the prebiotic for 14 days (Figure 1). Pyrosequencing of 
the regions V1–V2 of the 16S rRNA gene from 39 fecal samples using the universal 
bacterial primers 8F and 338R resulted in an average of 4,316±1,095 sequences per sample. 
A total of 172,636 sequences were assigned to 3,366 Operational Taxonomic Units (OTUs) 
at ≥ 97% similarity, clustering into 78 genera, 18 classes and 9 phyla. The overall 
composition of the fecal microbiome without dietary supplementation (n= 27) was 
dominated by the phyla Firmicutes (59.2% ± 22.4%) and Bacteroidetes (37% ± 23.6%) 
(Figure 2a), in accordance with previous reports of the gut microbiome composition of wt 
129 mice (48). Other phyla detected included Deferribacteres (1.9% ± 2.0%), Proteobacteria 
(0.8% ± 0.6%) and Actinobacteria (0.6% ± 0.6%) (Figure 2a). Representatives of the 
Tenericutes and TM7 phyla were also detected at low levels (<0.5%). At the order level, the 
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predominant groups were Lactobacillales (40% ± 25.8%), Bacteroidales (37% ± 23.6%) and 
Clostridiales (17.6% ± 15.4%) (Figure 2b). Composition of the gut microbiome of individual 
mice showed that Bacteroidetes was the phylum predominant in males while Firmicutes was 
more abundant in female mice at day 1, with the exception of mice C2M3 and C4M3 
(Supplementary Figure 1).
Sequencing of 16S rRNA amplicons from intestinal samples using a mixture (4:1) of 
forward primers 8F and B8F for the specific detection of Bifidobacterium as described by 
Martinez et al. (32) yielded a total of 50,716 sequences that were assigned to 362 OTUs at ≥ 
97% similarity. As in stools, Firmicutes and Bacteroidetes were the dominant taxa but 
proportions of both phyla were similar (46.7% ± 15.2% and 42.5% ± 18.3%, respectively; 
Figure 2c). Abundance of Deferribacteres (5.1% ± 8.9%) and Proteobacteria (1.6%±1.3%) 
was higher in intestinal contents than fecal samples (1.9% ± 2.0% and 0.7% ± 0.6% 
respectively) although differences did not reach statistical significance. Interestingly, 
abundance of the order Lactobacillales in intestinal contents was low (2.5% ± 2.1%) 
compared to stool samples (40% ± 17.5%), while abundance of Clostridiales was higher in 
intestinal contents (36.0% ± 16.3%) than in fecal samples (17.0% ± 12.3%).
Alpha diversity analysis performed in 2,700 randomly selected sequences per sample 
showed that the fecal microbiome diversity and richness increased over time in prebiotic-fed 
mice (Table 3). A small, but statistically significant effect on variables was observed for 
treatment suggesting that the fecal microbiome composition was modified by the prebiotic 
(ANOSIM R = 0.1127, p= 0.025) (Figure 3).
Sex had an apparent effect on the fecal microbiota of wt 129 mice
In our study, unweighted PCoA analysis of samples showed a clear clustering of samples by 
sex (Supplemental Figure 2a and 2b). However, since we applied the treatment per pen, and 
we had only one pen per interaction of factors, data was insufficient to draw significant 
conclusions. Control males had significantly lower bacterial diversity (PD = 7.8 ± 1.6 in 
stools and PD = 9.5 ± 1.0 in intestinal contents) compared to control females (PD = 15.1 
± 3.4 in stools and PD = 13.0 ± 0.6 in intestinal contents). We identified significant 
differences in the abundance of fifteen genera belonging to the phyla Actinobacteria, 
Proteobacteria, Bacteroidetes, Firmicutes and Tenericutes between genders (Supplemental 
Figure 2). Specifically, the relative abundance of nine genera (Anaeroplasma, Helicobacter, 
Butiricicoccus, Roseburia, Coprococcus, Lactobacillus, Alistipes, Odoribacter and 
Asaccharobacter) was significantly higher (between 1- and 80-fold) in females than males. 
In contrast, abundance of eight genera (Parasuterella, Coprobacillus, Anaerostipes, 
Anaerovorax, Hidrogenoanaerobacterium, Eubacterium, Enterococcus and Bacteroides was 
higher (between 1.3- and 10-fold) in the microbiota of male mice. Since, no male mice were 
included in the prebiotic-fed group and to identify the GOS90-specific impact on the gut 
microbiota, only samples from female mice (mice without dietary modification [n=15], 
GOS90-fed mice at days 7 [n=6] and 14 [n=6]) were considered for further analysis.
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Dietary GOS90 influenced the composition of the gut microbiome
GOS90 feeding resulted in statistically insignificant increases in relative abundance of 
Firmicutes (Control = 70% ± 20.8%; GOS90 = 80% ± 17.5%), especially Lactobacillales 
(Control = 48% ± 29.11%; GOS90 = 57%± 29.8%), and decreases of Bacteroidetes (Control 
= 25% ± 20.9%, GOS90 = 16.7% ± 15.7%), especially the order Bacteroidales (Figure 2). 
We observed a high inter-individual variation, but despite this variation, GOS90 feeding was 
associated with an underrepresentation of three Bacteroidales taxa: unclassified 
Bacteroidales (Steel Dwass All Pairs p=0.02), Parabacteroides (p=0.1) and unclassified 
Rikenellaceae (p=0.07) after 14 days (Figure 4). In addition, Helicobacter (p=0.005), 
Ruminococcus (p=0.02) and Clostridium (p=0.1) were underrepresented at days 7 and 14 
compared to the control.
Analysis at OTU level showed that 14 out of 15 Lactobacillus OTUs impacted by GOS 
showed an increased abundance (Supplementary Figure 3). Likewise, although total 
proportional amounts of Bacteroidetes (Bacteroidales) declined after 14 days, GOS90 
increased abundance of specific Bacteroides OTUs at days 7 and 14. Additionally, within 
Clostridiales we observed an increased abundance of six Lachnospiraceae OTUs, three 
Ruminococcaceae OTUs, and one Clostridium OTU at the end of the feeding trial.
The analysis of intestinal contents with a combination of Universal and Bifidobacterium-
specific primers resulted in similar changes at the phylum level as stools, with increased 
abundance of Firmicutes and decreased Bacteroidetes in prebiotic-fed mice. Due to the small 
sample size (n=5) owing to depletion of 4 samples (original n=9 female mice) we did not 
perform statistical analyses on abundance of bacterial taxa of intestinal samples from female 
mice. However, we observed that, unlike stools that showed an increase in the order 
Lactobacillales, in intestinal contents there was an increased abundance of the order 
Clostridiales (Figure 2d) and, similar to stool samples, we observed a marked reduction in 
the abundance of unclassified Bacteroidales (control = 0.02 ± 0.007; GOS90 = 0.005 
± 0.002).
Abundance of Bifidobacterium species in the fecal microbiome of prebiotic-fed mice 
showed high inter-individual variation
Since the universal primers used in our first 16S amplicon sequencing experiment have been 
reported to under-detect Bifidobacterium (49), extensively reported to be increased by GOS 
feeding (10, 18, 19), we performed additional amplicon pyrosequencing of fecal samples 
using Bifidobacterium-specific primers (32). Sequencing resulted in an average of 3,328 
± 1,319 sequences per sample (149,962 sequences in total), which were assigned to 769 
OTUs. Thirty-six OTUs were specifically assigned to the phylum Actinobacteria and nine to 
the genus Bifidobacterium. We observed an increasing trend in the abundance of 
Actinobacteria, Bifidobacteriaceae and Bifidobacterium associated with GOS90 feeding 
(Figure 5). A closer examination of samples at day 14 revealed that the effect of GOS90 
varied among individual mice. From day 7 to 14, abundance of Bifidobacterium increased 
2.5- to 15-fold in four out of six GOS90-fed mice while abundance of this group decreased 
in the other two animals. Following the designation by Davis et al. (10), we denominated the 
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animals that showed increased abundance of Bifidobacterium “responders” and the ones that 
showed no increase “non-responders” (Figure 5).
Bifidobacterium adolescentis, B. catenulatum, B. lactis, and B. gallicum were increased in 
4 out of 6 prebiotic-fed mice
We next aimed to identify specific Bifidobacterium species affected by GOS90. Primers 
specific for nine species of Bifidobacterium, genus Bifidobacterium, family 
Bifidobacteriaceae and phylum Actinobacteria were used to quantify bacterial groups by 
high-throughput qPCR using the Access Array 192.24 (Fluidigm®). We used two primer sets 
for each taxon, targeting the 16S ribosomal gene and the chaperonin groEL. Positive 
correlations (Pearson’s r > 0.5) were observed between the two methods for 16S and groEL 
primers sets (Supplementary Figure 4)
Data showed an increased abundance of Bifidobacteriaceae and Bifidobacterium (13- and 4-
fold, respectively) after 14 days (Figure 6) as well as a marked increase in the abundance of 
B. adolescentis, B. catenulatum, B. lactis and B. gallicum. The B. catenulatum group (B. 
catenulatum and B. pseudocatenulatum) exhibited the largest increase in the GOS-fed group.
A linear fit analysis performed to assess the correlation between 16S rRNA and groEL data 
for detection of Bifidobacterium species showed Pearson’s r correlation values > 0.70 for B. 
longum, B. adolescentis, B. gallicum and B. lactis, while lower correlation indices 
(Pearson’s r < 0.70) were observed for B. catenulatum, B. angulatum, B. dentium, B. 
bifidum and B. breve (Supplementary Figure 5). Data suggest that all primers targeting the 
groEL gene were adequate for all Bifidobacterium species with the exception of B. breve, 
while primers targeting the 16S rRNA gene were less optimal for B. angulatum, B. longum 
and B. bifidum.
Predictive analysis of metabolic functions associated with GOS90 feeding
We next used PICRUSt to predict metabolic pathways and enzymes influenced by GOS. We 
identified a total of 328 pathways in all samples (control and prebiotics). We observed a non 
significant (Steel Dwass All Pairs p=0.14) over-representation of the galactose metabolism 
pathway in the GOS90 group at the end of the trial (Figure 7a). When data were stratified 
into responders and non-responders, a clear over-representation of this pathway was 
observed in responders (p=0.01), while representation of this pathway in non-responders 
was similar to the control group (Figure 7a). Similar patterns were observed for the starch 
and sucrose metabolism pathways (data not shown).
GOS90 feeding also resulted in the predicted over-representation of a D-lactate 
dehydrogenase and a lactate transporter from the LctP family (Figure 7b), and one gene 
involved in the metabolism of galactose, 6-phospho-β-galactosidase [EC 3.2.1.85] (Figure 
7c). When data were further divided into responders and non-responders, differences became 
significant or close to significant for responders (Figures 7b and 7c).
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Stool of prebiotic fed mice showed reduced concentrations of acetate, lactate and butyrate
Intermediate and end metabolites from GOS utilization (SCFAs, succinate, glycerol, lactate, 
glucose, aminobutyrate and galactose) were measured in stool samples by chromatography 
to determine if the prebiotic influenced SCFA generation. Butyrate, lactate, acetate, 
propanoate, glucose and glycerol were detected at their highest concentration in both groups 
at day 1 (no dietary modulation). Levels of isobutyrate, valerate, 2-aminobutyrate, succinate 
and galactose were on average below 1 µmol/g fecal sample (Table 4). We observed a 
significantly lower abundance of acetate (unpaired t-test p=0.03), and borderline significant 
decreases of lactate (p=0.09), and butyrate (p=0.1) in prebiotic-fed mice compared to control 
mice. The same results were observed when data from responders and non-responders were 
analyzed separately (not shown).
GOS90 did not modify inflammatory biomarkers
Pro-inflammatory cytokines IL-6, IL-12, IL-1β, IFN-γ, TNF-α and the anti-inflammatory 
cytokine IL-10 were quantified by ELISA in the proximal and distal colon of the control and 
GOS90 groups. No significant differences were detected between groups; however, we 
observed different cytokine profiles in the proximal and distal colon in both groups. 
Specifically, in the distal colon the pro-inflammatory cytokines IL-6 and IL-12 were 
detected at lower levels while levels of TNF-α were higher. Levels of IL-1β and IFN-γ in 
both colon sections, and IL-10 in the distal colon, were below the method’s detection limits 
(Table 5).
Discussion
The aim of this study was to evaluate the impact of a highly pure GOS formulation (GOS90)
(23), composed of GOS (90%) and lactose (10%) on the gut microbiome of wt 129 mice. No 
significant differences were observed in starting values at day 1. In addition, since we 
intended to focus our analysis on the longitudinal effect of GOS90 rather than cross-
sectional differences, we performed most comparisons between the GOS90 group at 7 and 
14 days and the overall control. Our data showed that GOS90 feeding for 14 days resulted in 
an increase of fecal relative abundance of the bifidobacteria Bifidobacterium adolescentis, B. 
catenulatum, B. lactis, B. gallicum and specific OTUs of Lactobacillus, Bacteroidetes and 
Clostridiales. Duration of treatment was chosen based on previously published research in 
humans and mice, which reported range treatments from 7 days (50, 51) to 12 weeks (10). 
Our study showed an specific increase of B. catenulatum and a decrease of Clostridium at 
day 7 of the feeding trial in agreement with the study by Nakayama and Oish (50),which 
reported that, in mice, 7 days of GOS treatment were enough to identify changes in the 
microbiota that resulted in decreases of Clostridium and E. coli and increases in 
Bifidobacterium abundances.
Our approach used a dose of 0.26 g GOS90/kg weight administered daily over 14 days. 
Previous human studies reported a prebiotic impact on gut microbiome composition at doses 
ranging from 4 to 20 g/day with inulin, fructo-oligosaccharides (FOS) and GOS (52). With 
FOS or inulin doses higher than 15 g/day (equivalent to 0.21 g/kg weight/day) inducing 
flatulence or abdominal bloating (53, 54). Most of the studies with GOS in humans used a 
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recommended dosage of 8 to 15 g/day (0.11 to 0.21 g/kg weight/day) (11), although the 
bifidogenic effect has been observed at doses as low as 5 g/day (10, 17, 55). In animal 
studies, increased abundance of Bifidobacterium and Lactobacillus has been reported in 
mice fed 1 g of GOS/kg weight(56) and with diets supplemented with Oligomate at a 1% 
concentration (57). The impact of GOS on the gut microbiome of laboratory rats has not 
been studied but animals administered between 2.5 and 5g/kg weight/day of GOS showed no 
significant adverse toxicological effects attributable to the prebiotic (55).
A fiber-rich diet has been associated with increased microbial diversity (58), while a low gut 
microbial diversity has been correlated with recurrent Clostridium difficile infection, 
Crohn’s disease, and obesity (59, 60). In this study, we observed a marginal, statistically 
insignificant increase in diversity and species richness in GOS90-fed mice. These results 
suggest that longer periods of prebiotic feeding could result in a higher bacterial diversity.
Interestingly, we observed gender-specific differences in the fecal microbiome of control 
mice, with lower bacterial diversity in males and an over-representation of the butyrate 
producers Roseburia and Butyricicoccus in female mice. A study by Bernbom et al. showed 
that the fecal microbiota of SPF rats and human microbiota-associated rats clustered 
according to the gender of the host animal (61). Our results are consistent also with the 
observations by Markle et al. who suggested that sex hormones could influence microbial 
populations (62). Moreover, a type 1 diabetes study in non-obese diabetic (NOD) mice 
showed a hormone-supported increase of selected microbial taxa, which may work as a 
positive-feedback mechanism contributing to the sexual dimorphism of autoimmune 
diseases (63). More recently, Bolnick et al.(64) analyzed associations between gut 
microbiota and sex*diet, and showed that microbial responses to diet depended on sex in 
laboratory mice fed either a control diet or a high fat diet. These and our data warrant more 
studies to elucidate the mechanisms driving differences in the gut microbiota associated with 
sex*diet.
Impact of GOS90 on the composition of the fecal microbiome varied between individual 
mice. Moreover, since in our study control mice did not receive any carrier solution, it is 
possible that stress had an additional impact on GOS90 fed mice. Specifically, four out of 
six treated mice (responders) showed an increase of up to 15-fold in Bifidobacterium 
abundance while two animals (non-responders) showed no response. The selective response 
to prebiotics has been previously reported in humans (10, 17). Also, the enrichment of 
bifidobacteria at the expense of other groups such as Bacteroides has been reported in 
humans fed GOS (10, 19). In addition, in our study we detected a reduced representation of 
other Bacteroidetes taxa including unclassified Bacteroidales and Parabacteroides. Species 
of these taxa are often associated with opportunistic infections, mainly intra-abdominal and 
systemic, as well as harboring some antimicrobial resistance traits that could be transferred 
to other strains (65).
Since 16S amplicon sequencing methods do not have enough sensitivity to identify bacterial 
taxa at the species level, we developed and optimized a high-throughput real-time qPCR 
assay using the Biomark instrument by Fluidigm to quantify bifidobacterial species. 
Although we observed an overall positive correlation between primers targeting the 16S 
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rRNA and groEL genes for detection of Bifidobacterium species, our analysis suggests that 
primers targeting the groEL gene efficiently detected and quantified the species selected in 
our study with the exception of B. lactis. Conversely, primers targeting the 16S rRNA gene 
were less optimal for B. angulatum, B. longum and B. bifidum. The groEL gene has been 
reported to be more discriminative for the detection and quantification of Bifidobacterium 
species (46), in part because it is present in one copy per genome. We observed striking 
differences in the levels of detection of the B. catenulatum group with the two different 
primer sets, which are explained by the different specificity of each set. The groEL primer is 
specific for B. catenulatum, while the oligonucleotide targeting the 16S ribosomal gene can 
detect both B. catenulatum and B. pseudocatenulatum. This result indicates a more 
pronounced expansion of B. pseudocatenulatum in response to the prebiotic.
Data obtained with this new platform confirmed pyrosequencing results and showed an 
increased abundance of B. pseudocatenulatum, B. gallicum, B. lactis and B. angulatum in 
prebiotic-fed mice at day 14. The most dramatic effect was observed in the B. catenulatum 
group (B. catenulatum and B. pseudocatenulatum) with a 100-fold expansion. Significant 
GOS-induced increases of this group have been also reported in humans (10). In fact, a study 
that tested the growth of Bifidobacterium species with different prebiotics showed that, of 
those tested, GOS was the only prebiotic to support growth of B. pseudocatenulatum (66). 
An increase of 13-fold was also observed in B. angulatum; β-galactosidases extracted from 
B. angulatum have been used for the utilization and generation of GOS with high 
concentrations of lactose (67). Finally, we also observed proliferation of B. lactis, a species 
widely used as a probiotic capable of using GOS (68, 69). In addition, synbiotics—where 
this species and GOS act synergistically—have been used in different clinical studies 
proving their beneficial effect on health (70, 71).
In this study, we observed a decreased abundance of Helicobacter and Clostridium in 
GOS90-fed mice. Previous studies have reported a reduction of colitis severity in Smad3-
deficient mice treated with the pathogen Helicobacter as well as reduction of Clostridium by 
GOS in vitro and in mice (72–74). In addition to their impact on gut bacterial taxa, 
prebiotics have been shown to enhance host health by directly inhibiting adherence of 
pathogens to the host epithelial cell surface (75) and modulating the colon 
microenvironment, which results in a reduction of intestinal infections (13, 76). The role of 
Helicobacter in gastric cancer is well-documented (77, 78) and recent reports suggest a 
potential role of this bacterium in IBD (79–81). Likewise, Clostridium has been correlated 
with increased incidence and growth of colonic tumors in animal studies (82, 83). Further 
studies are needed to elucidate the role and potential mechanisms involved in reduction of 
pathogenic species by the prebiotic used in this study.
Short-chain fatty acids (SCFAs), especially butyrate, have an important role in host health 
since they function as energy source for host tissues, have antimicrobial activity and have 
anti-inflammatory and anti-proliferative properties (84, 85). In the present study, we 
observed a significant decrease in the fecal concentration of acetate, lactate, and butyrate in 
prebiotic-fed mice. SCFAs’ fecal concentration reflects the amount remaining after colonic 
absorption. Although an inhibited microbial production of these SCFAs cannot be excluded, 
the reduction of these metabolites could reflect an increase in colonic absorption and 
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reduced excretion. In fact, Vogt and Wolever reported a negative correlation between acetate 
fecal concentration and absorption suggesting that fecal SCFA concentrations may better 
reflect colonic SCFA absorption than production (86). Undoubtedly, these results warrant 
further experiments to elucidate generation and fate of SCFA in the colon of GOS90-fed 
animals.
We used PICRUSt to infer metagenome functional content from 16S rRNA amplicon 
sequencing input data. Since GOS are composed of galactose and glucose molecules joined 
in a β-configuration, we specifically looked at pathways and enzymatic functions involved in 
galactose metabolism. We observed an enrichment of the galactose metabolism pathways in 
the prebiotic group that became more evident when only responders were included in the 
analysis. We also observed an over-representation of pathways involved in the metabolism of 
starch and sucrose, which suggest that GOS-metabolizing bacteria could also have the 
ability to use other prebiotics such as resistant starch. In fact, studies have reported increases 
in the relative abundance of Bifidobacterium and Lactobacillus when starch was used as 
prebiotic (89, 90). A lactate dehydrogenase, an enzyme that catalyzes the conversion from 
pyruvate to lactate, and a lactate transporter from the LctP family were also over-represented 
in the prebiotic group. We also observed a significant over-representation of the 6-phospho-
beta-galactosidase [EC 3.2.1.85], an enzyme involved in the utilization of GOS that 
hydrolyzes the 6-phospho-β-D-galactosides previously phosphorylated and translocated by 
PTS transporters. Otherwise, we did not observe significant changes in β-galactosidases that 
are more commonly used by some lactic acid bacteria or by Bifidobacterium (91). This 
could be explained by the GOS90 fermentation by other species whose abundance was 
higher than Bifidobacterium and that use mainly the PEP-PTS system to ferment galactose, 
species such as Streptococcus, Lactococcus and some species of Lactobacillus, like L. casei 
and L. acidophilus (92, 93).
Studies have shown that prebiotics can attenuate the pro-inflammatory response in intestinal 
epithelial cells in animals model of disease (94–96). Modulation of inflammatory 
biomarkers by GOS90 was not observed in prebiotic fed mice due most probably to the fact 
that this study was conducted in healthy wt mice with no inflammatory conditions. Overall, 
in this study we demonstrated that GOS90 has the potential to modulate the gut microbiota 
and its metabolites, specifically enriching for Bifidobacterium and Lactobacillus and 
promoting a reduction in Bacteroidales and potential pathogens such as Clostridium and 
Helicobacter in mice. Future studies will evaluate this prebiotic alone or in conjunction with 
probiotics in animal models of inflammation and colon cancer to evaluate its potential role 
in prevention and treatment.
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Figure 1. Study experimental design
Thirteen germ-free mice (GF) were colonized by gavage from a pool of specific pathogen-
free (SPF) donors. After 9 days, GOS90 was delivered orally to six mice for 14 days. Fecal 
samples were collected at three time points (1, 7 and 14 days) and intestinal contents were 
collected at day 14. Day in negative numbers indicate days before starting the feeding trial.
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Figure 2. Microbiome composition of stools and intestinal contents
Phylum and order level distributions of fecal (a,b) and intestinal contents (c,d) microbiota by 
feeding group (control and GOS90) at day 7 and 14 of the study. The control group included 
all stool samples from mice not fed the prebiotic. Universal 8F-338R primers were used for 
stool samples and a combination of the universal and Bifidobacterium-modified primer set 
were used for the intestinal contents.
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Figure 3. Unweighted Principle Coordinate Analysis (PCoA) plot of fecal microbiome from 
control (n=15) and prebiotic-fed female mice (n=12)
Each dot represents one fecal sample. All time points were included in the analysis. 
ANOSIM R and P values are indicated in the Figure.
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Figure 4. Mean relative abundance of underrepresented genera at days 7 (n=6) and 14 (n=6) of 
GOS90 feeding compared to control samples (n=15)
Error bars indicate standard deviations (Steel-Dwass All Pairs, * p ≤ 0.05, § p ≤ 0.1).
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Figure 5. Mean relative abundances of a) phylum Actinobacteria, b) family Bifidobacteria and c) 
genus Bifidobacterium by feeding group at days 7 (n= 6) and 14 (n=6)
Data was stratified in responders (n=4) showing increased abundance of Bifidobacterium in 
response to prebiotic feeding, and non-responders (n=2), showing no change in response to 
prebiotic feeding. Error bars indicate the 10th and 90th percentile. Steel-Dwass All Pairs test 
*p ≤ 0.05, § ≤ 0.1.
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Figure 6. Absolute quantification of Bifidobacterium species by high-throughput qPCR
Changes in abundance between GOS90 (n=12) and controls (n=15) are shown at a) day 7 
(n=6) and b) day 14 (n=6). Left panels show data generated using GroEL-specific primers, 
right panels show data generated using 16S rRNA gene-specific primers.
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Figure 7. Relative abundances of specific KEGG pathways and enzymes impacted by GOS90 
feeding
a) Galactose metabolism pathway, b) 6-phospho-beta-galactosidase, c) D-lactate 
dehydrogenase and d) lactate transporter. Control n=15, GOS90 at day 7 n=6, GOS90 at day 
14 n=6, Responders to GOS90 at day 14 (n=4) and Non-responders to GOS90 at day 14 
(n=2). Boxes represent data between 25th and 75th percentile. Error bars indicate the 10th 
and 90th percentile. Steel-Dwass All Pairs tests § p ≤ 0.1, *p ≤ 0.05.
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Table 1
Bifidobacterium strains used in the present study as positive and negative controls.
Bifidobacterium strain Sample original ID Origin
B. longum longum NCK 1575 Kindly provided by T. Klaenhammer (NC State University)
B. longum infantis ATCC 15697 ATCC
B. pseudocatenulatum Human stool sample Kindly provided by T. Keku (UNC-Chapel Hill)
B. bifidum ATCC 29521 ATCC
B. breve ATCC 15700 ATCC
B. lactis NCK 1573 Kindly provided by T. Klaenhammer (NC State University)
B. adolescentis Human stool sample Kindly provided by T. Keku (UNC-Chapel Hill)
B. bifidum NCK 2083 Kindly provided by T. Klaenhammer (NC State University)
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Table 3
Phylogenetic diversity and species richness of control and GOS90 samples at days 7 and 14. Universal 
8F-338R primers were used for 16S amplicon sequencing of stool samples and a combination of the universal 
and Bifidobacterium-modified primer set (4:1) were used for intestinal contents.
Stool samples Intestinal contents
Phylogenetic
diversity
Species
richness
Phylogenetic
diversity
Species
richness
Control 15.0 ± 6.1 138.2 ± 72.9 10.6 ± 2.0 117.0 ± 56.8
GOS90 Day 7 16.5 ± 4.7 157.8 ± 60.8 - -
GOS90 Day 14 17.5 ± 4.3 170.5 ± 65.0 10.9 ± 2.9 124.4 ± 59.9
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Table 5
Cytokine levels of the proximal and distal colon of control (n=3) and GOS90-fed female mice at day 14 (n=6). 
Quantification was performed by ELISA. Values are expressed as pg/mg protein.
Proximal colon Distal colon
Control GOS90 Control GOS90
IL-12 19.37 ± 14.57 16.7 ± 10.94 6.50 ± 3.38 6.00 ± 14.95
IL-6 14.71 ± 10.98 34.38 ± 20.91 9.40 ± 6.17 14.09 ± 14.95
TNF-α 20.80 ± 8.46 22.34 ± 6.01 47.92 ± 6.39 47.24 ± 9.63
IL-10 10.74 ± 14.71 4.83 ± 7.44 <LOD <LOD
IFN-γ <LOD <LOD <LOD <LOD
IL-1β <LOD <LOD <LOD <LOD
LOD: Limit of detection
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